Clinical Trials on Bile Duct Obstruction in Argentina

Total 248 results

Mirum Pharmaceuticals, Inc.

Active, not recruiting

An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

Progressive Familial Intrahepatic Cholestasis (PFIC)

United States, Argentina, France, Singapore, United Kingdom, Belgium, Turkey, Austria, Brazil, Canada, Colombia, Germany, Italy, Lebanon, Mexico, Poland
Mirum Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) (MARCH-PFIC)

Progressive Familial Intrahepatic Cholestasis (PFIC)

Italy, United States, Argentina, France, Singapore, United Kingdom, Austria, Brazil, Mexico, Lebanon, Germany, Turkey, Poland, Belgium, Canada, Colombia, Hungary
Inmunotek S.L.
LAT Research; Xolomon Tree S.L.

Not yet recruiting

Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract (MM09-SLIM)

Allergic Rhinitis | Allergic Asthma | Allergic Rhinoconjunctivitis | Allergy to House Dust Mite

Argentina
Zydus Therapeutics Inc.

Not yet recruiting

Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States, Turkey, Argentina
Intercept Pharmaceuticals

Terminated

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

Liver Cirrhosis, Biliary

United States, Argentina, Spain, Belgium, Germany, Canada, Australia, Estonia, Brazil, Hungary, Italy, Lithuania
Zydus Therapeutics Inc.

Active, not recruiting

Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis (EPICS-III)

Primary Biliary Cholangitis

United States, Argentina, Iceland, Turkey
CymaBay Therapeutics, Inc.

Completed

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, United Kingdom, Israel, France, Korea, Republic of, Australia, Italy, Hungary, Germany, Romania, Belgium, Canada, Greece, New Zealand, Austria, Serbia, Russian Federation, Argentina, Mexico, Netherlands, Chile, Polan...
CymaBay Therapeutics, Inc.

Completed

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, France, Korea, Republic of, Denmark, Australia, Italy, United Kingdom, Belgium, Canada, Russian Federation, Romania, Germany, Hungary, Mexico, Turkey, Argentina, Austria, Chile, Czechia, Greece, Israel, New Zealand and more
Intercept Pharmaceuticals

Terminated

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT)

Liver Cirrhosis, Biliary

United States, Spain, Korea, Republic of, Australia, Finland, Israel, Lithuania, United Kingdom, Belgium, Netherlands, Estonia, Brazil, Italy, Serbia, Sweden, Argentina, Austria, Canada, Chile, Denmark, France, Germany, Hong Kong, Hun... and more
CymaBay Therapeutics, Inc.

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Primary Biliary Cirrhosis

United States, Korea, Republic of, Belgium, Spain, France, Switzerland, Romania, United Kingdom, Austria, Israel, Australia, Argentina, Canada, Chile, Germany, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Czechia, New Zealand, Turke... and more
Ipsen

Active, not recruiting

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (ELATIVE)

Primary Biliary Cirrhosis

United States, France, Spain, Belgium, Germany, Switzerland, Brazil, United Kingdom, Argentina, Canada, Chile, Italy, South Africa, Turkey
GlaxoSmithKline

Recruiting

Linerixibat Long-term Safety, and Tolerability Study (LLSAT)

Cholestasis

United States, France, Japan, United Kingdom, Bulgaria, Germany, Greece, Italy, China, Argentina, Belgium, Brazil, Canada, Czechia, Israel, Mexico, Poland, Russian Federation, Spain, Switzerland
Hospital Italiano de Buenos Aires

Unknown

Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery (ILEUS)

Postoperative Ileus

Argentina
PH&T S.p.A.

Unknown

Demonstrate the Therapeutic Clinical Equivalence of Two Mometasone Nasal Sprays (PHT-01-12)

Nasal Obstruction | Sneezing | Itching

Argentina
GlaxoSmithKline

Active, not recruiting

Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Pruritus

United States, France, Spain, Israel, Belgium, Canada, Czechia, Italy, United Kingdom, China, Germany, Mexico, Japan, Brazil, Poland, Russian Federation, Greece, Argentina, Switzerland, Bulgaria
Hospital Italiano de Buenos Aires

Unknown

Hospitalary Chronic Obstructive Pulmonary Disease Registry

Death | COPD Exacerbations

Argentina
Hospital Italiano de Buenos Aires
Asociacion Argentina Medicina Respiratoria (AAMR)

Unknown

Association Between Testosterone Levels and COPD Severity (COPDTESTO)

Chronic Obstructive Pulmonary Disease | Hypogonadism

Argentina
AstraZeneca

Completed

SABINA INTERNATIONAL

Asthma

Argentina
GlaxoSmithKline

Completed

Prednisolone Novel Endpoint Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Chile, South Africa, New Zealand
Hospital General de Niños Pedro de Elizalde

Completed

Efficacy of Nebulized Hypertonic Saline in the Treatment of Acute Bronchiolitis (Hypertonic)

Bronchiolitis

Argentina
Novartis Pharmaceuticals

Completed

Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD) (Advantage)

Pulmonary Disease, Chronic Obstructive (COPD)

Argentina
Universidad Nacional de Rosario

Completed

Asthmatic Subjects Could Live Without Short Acting beta2 Agonists (NOSABA)

Asthma Chronic

Argentina
Novartis Pharmaceuticals

Completed

Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices

Pulmonary Disease, Chronic Obstructive (COPD)

Argentina
AstraZeneca

Completed

Prevalence Study and Regular Practice Among General Practitioners in Populations at Risk of Chronic Obstructive Pulmonary Disease (COPD) in Latin America (PUMA PROJECT)

Chronic Obstructive Pulmonary Disease

Venezuela, Colombia, Argentina, Uruguay
AstraZeneca

Completed

Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101)

Asthma

Argentina
AB Science

Completed

Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels

Asthma

Malaysia, Argentina, Peru, Philippines, Ukraine
Novartis Pharmaceuticals

Withdrawn

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Chronic Obstructive Pulmonary Disease

Colombia, India, Belgium, Argentina, Czech Republic
AstraZeneca

Recruiting

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). (ATHLOS)

Chronic Obstructive Pulmonary Disease

Germany, Spain, United States, China, Korea, Republic of, Argentina, United Kingdom, Canada
Novartis Pharmaceuticals

Completed

Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD (COMBINE)

Chronic Obstructive Pulmonary Disease

Argentina, Dominican Republic, Panama, Mexico, Brazil, Chile, Ecuador, Honduras
Novartis Pharmaceuticals

Completed

A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149

Chronic Obstructive Pulmonary Disease

China, Argentina, Taiwan, Chile
AstraZeneca

Completed

A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy

Chronic Obstructive Pulmonary Disease COPD

United States, Netherlands, Argentina, South Africa, Chile, Peru
GlaxoSmithKline

Completed

A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Russian Federation, Ukraine, Mexico
Novo Nordisk A/S

Terminated

Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD) (iINHALE 8)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Chronic Obstructive Pulmonary Disease

Slovakia, Argentina, India, Turkey, Romania, Taiwan, Thailand
Symetis SA

Completed

ACURATE TA™ Valve Implantation: SAVI Registry (Surveillance Plan #2011-02) (TA-SAVI)

Symptomatic Aortic Stenosis

Germany, Italy, Argentina, Switzerland
P+F Products + Features GmbH
Meditrial USA Inc.

Recruiting

Pivotal Study of the Vienna Transcatheter Self Expandable Aortic Valve SE System (VIVA)

Symptomatic Aortic Stenosis

Spain, Argentina, Lithuania, Portugal, Brazil, Chile
GlaxoSmithKline

Completed

Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Germany, Estonia, Ukraine, Korea, Republic of, Norway, Czechia
GlaxoSmithKline

Completed

Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Spain, Chile, Germany, Korea, Republic of, Bulgaria, Brazil, Slovakia
Pfizer

Completed

A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).

Chronic Obstructive Pulmonary Disease

Australia, Netherlands, Canada, Korea, Republic of, Argentina, Hungary, South Africa, France, Russian Federation, Chile, Czechia, Greece, United Kingdom
AstraZeneca

Completed

Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

Chronic Obstructive Pulmonary Disease | COPD

United States, Argentina, Canada, Colombia, Mexico, Peru
Sanofi
Regeneron Pharmaceuticals

Completed

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Ukraine, Argentina, Chile, Poland, Russian Federation, Turkey, United States, Australia, Canada, Germany
Hoffmann-La Roche

Completed

A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Canada, Bulgaria, Hungary, Russian Federation, Denmark, Argentina, Mexico, Poland
Pfizer

Completed

A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Costa Rica, Brazil, Chile, Mexico, Argentina
Pfizer

Terminated

Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD

Pulmonary Disease, Chronic Obstructive

Australia, Canada, Czech Republic, Croatia, Spain, Hungary, Argentina, Singapore, United Kingdom, Chile
University Hospital, Ghent

Completed

VeSpAR: Comparing Vessel-Sparing Anastomotic Repair and Transecting Anastomotic Repair in Isolated Short Bulbar Strictures. (VeSpAR)

Urologic Diseases | Surgery | Urethral Stricture

Belgium, United States, Argentina, China, Mexico, Portugal, Spain, United Kingdom
Daiichi Sankyo, Inc.

Completed

SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)

Cachexia

United States, Argentina, Chile, Guatemala, Honduras, Romania
AstraZeneca

Completed

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Germany, Argentina, Bulgaria, Poland, Turkey, Mexico, United Kingdom
GlaxoSmithKline

Completed

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Chile, Romania, Canada
Pfizer

Completed

A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD

Pulmonary Disease, Chronic Obstructive

Australia, United Kingdom, Argentina, Germany, India
GlaxoSmithKline

Completed

A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma

Asthma

Argentina
Novartis Pharmaceuticals

Completed

Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

Colombia, India, Korea, Republic of, Poland, Croatia, Estonia, Hungary, United Kingdom, Israel, Latvia, Turkey, Argentina, Panama, Mexico, Russian Federation, Serbia, Slovenia

Clinical Trials on Bile Duct Obstruction in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations